Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LILAC: Trofinetide Open-Label Extension in Rett Syndrome
NCT04279314Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Aug 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trofinetide in Rett syndrome (RTT), sponsored by Acadia Pharmaceuticals. Primary endpoints: Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to AEs at 40 weeks, Subjects With Post-baseline Potentially Clinically Important Changes in ECG at 40 weeks and 3 more. Started Jan 2020; status: completed.
02
Drugs
trofinetide
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT04279314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04279314.